About NewCardio

About NewCardio

NewCardio is a Silicon Valley based company with the mission of fully developing and commercializing a three dimensional (3D) approach to electrocardiography.

The company is developing and validating a novel, patent pending electrocardiography (ECG) platform technology to dramatically improve the diagnostic accuracy and value of the standard 12 lead ECG for common acute and chronic heart disease and for evaluating cardiac safety of new drugs. NewCardio platform technology relies on the standard 12-lead ECG signal as the input, and thus requires no change in how the 12-lead ECG is obtained.

NewCardio's cardiac diagnostic products and services are used to determine the cardiac toxicity of new drugs in development, and to evaluate cardiac status during acute and chronic patient management both in and out of the clinical environment. NewCardio's 3-dimensional ECG approach allows faster, more accurate and less expensive assessment of cardiac status, and diagnosis of previously difficult or undiagnosable conditions, without much more expensive and not as widely available techniques.

NewCardio's services for clinical drug trials will help ECG core labs and pharmaceutical and biotech companies to rapidly detect cardiac toxicity, when present, for drugs involved in clinical development. In healthcare, the Company's diagnostic tools will substantially improve the accuracy and timeliness of the diagnosis and response to patients arriving at the emergency department with suspected myocardial infarction (MI). NewCardio's hand-held products could change the way patients with chronic heart conditions will monitor their disease outside the clinical setting.